Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C | Agenda Bookshop Skip to content
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
A01=Board on Population Health and Public Health Practice
A01=Committee on the Prevention and Control of Viral Hepatitis Infections
A01=Institute of Medicine
Age Group_Uncategorized
Age Group_Uncategorized
Author_Board on Population Health and Public Health Practice
Author_Committee on the Prevention and Control of Viral Hepatitis Infections
Author_Institute of Medicine
automatic-update
B01=Abigail E. Mitchell
B01=Heather M. Colvin
Category1=Non-Fiction
Category=MBN
Category=MJC
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€50 to €100
PS=Active
softlaunch

Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care.

Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood.

Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

Table of Contents
  • Front Matter
  • Summary
  • 1 Introduction
  • 2 Surveillance
  • 3 Knowledge and Awareness About Chronic Hepatitis B and Hepatitis C
  • 4 Immunization
  • 5 Viral Hepatitis Services
  • Appendix A: Committee Biographies
  • Appendix B: Public Meeting Agendas
  • Index
See more
Current price €53.19
Original price €55.99
Save 5%
A01=Board on Population Health and Public Health PracticeA01=Committee on the Prevention and Control of Viral Hepatitis InfectionsA01=Institute of MedicineAge Group_UncategorizedAuthor_Board on Population Health and Public Health PracticeAuthor_Committee on the Prevention and Control of Viral Hepatitis InfectionsAuthor_Institute of Medicineautomatic-updateB01=Abigail E. MitchellB01=Heather M. ColvinCategory1=Non-FictionCategory=MBNCategory=MJCCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€50 to €100PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 23 May 2010
  • Publisher: National Academies Press
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780309146289

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept